Physician profile
Michael Pfeiffer
NPI 1295078228
$8,981.39
in general payments reported to CMS, 2019-2025
24 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 87% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $593 · 2021: $737 · 2022: $2,319 · 2023: $1,493 · 2024: $1,369 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,976 · Travel and Lodging: $527 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,975.98 |
| Travel and Lodging | $527.40 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,730.10 | 2023-2025 | Inspire |
| Stryker Corporation | $2,084.71 | 2019-2025 | Scopis Ent, Audion Et Dilation System |
| Medtronic, INC. | $1,627.98 | 2021-2024 | Pteye Parathyroid Detection System, Sinuva |
| Optinose US, INC. | $875.63 | 2020-2024 | |
| Genzyme Corporation | $719.89 | 2021-2025 | |
| Aerin Medical INC. | $180.05 | 2024 | |
| Glaxosmithkline, LLC. | $166.60 | 2021-2024 | Nucala |
| Intersect Ent, INC. | $148.08 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $132.48 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $35.58 | 2023-2024 | Xolair |
| Amgen INC. | $34.00 | 2025 | |
| Merck Sharp & Dohme LLC | $31.79 | 2023-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $28.54 | 2019 | |
| Convatec INC. | $24.92 | 2023 | |
| Boston Scientific Corporation | $24.42 | 2023 | Watchman Access System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C2dx, INC | $23.08 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.75 | 2025 | Tezspire |
| Acclarent, INC | $19.62 | 2023 | Acclarent Aera |
| Alk-Abello, INC | $14.44 | 2019 | |
| Zimmer Biomet Holdings, INC. | $13.10 | 2024 | Traumaone |
| Bolder Surgical, LLC | $11.92 | 2022 | |
| Olympus America INC. | $11.89 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.56 | 2019 | |
| Ethicon US, LLC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pfeiffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.